Influence of pharmacogenetics on drug disposition and response

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 10-11, 1996, Pages 983-985

  Eichelbaum, M ^a   Evert, B ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Cytochrome P4502C19; Cytochrome P4502D6; Glucose 6 phosphate dehydrogenase; Pharmacogenetics

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450; DEBRISOQUINE; DRUG METABOLITE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MEPHENYTOIN; MORPHINE; SPARTEINE;

CONFERENCE PAPER; DRUG DISPOSITION; DRUG RESPONSE; ENZYME DEFICIENCY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; PHARMACOGENETICS;

EID: 0029808456     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb01154.x     Document Type: Conference Paper

References (21)

1. Garrod AE. The incidence of alcaptonuria: A study in chemical individuality. Lancet 1902; ii: 1616-20.
2. Vogel F, Motulsky AG. Human genetics. Problem and Approaches, 2nd edn. Springer-Verlag, Berlin. 1986.
3. Luzzatto L, Mehta A. Glucose-6-phosphate dehydrogenase deficiency. In: Scriver CR, Baudet AL, Sly WS, Vale D (eds). The metabolic basis of inherited diseases. McGraw-Hill, New York. 1989; Ch. 91.
4. Ruwende C, Khoo SC, Snow RW et al. Natural Selection of hemi-and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995; 376: 246-9.
5. Mahgoub A, Idle JR, Dring DG, Lancester R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 584-6.
6. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 1979; 16: 183-7.
7. Gonzales FJ, Skoda RC, Kimura S et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-6.
8. Heim MH, Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14: 49-58.
9. Broly F, Gaedigk A, Heim M, Eichelbaum M, Mörike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991; 10: 545-58.
10. Bertilsson L, Dahl M-L, Sjöqvist F et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63.
11. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelma-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl Acad. Sci. USA 1993; 90: 11 825-9.
12. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism: Clinical aspects. In: Kalow W (ed.). Pharmacogenetics of drug metabolism. Pergamon Press, New York. 1992; 625-48.
13. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of the knowledge of cytochromes P450(CYP)2D6 and 2C19. Clin. Pharmacokin. 1995; 29: 192-209.
14. Kroemer HK, Eichelbaum M. 'It's the genes, stupid.' Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci. 1995; 561: 2285-98.
15. Sjöqvist F. Pharmacogenetic factors in the metabolism of tricyclic antidepressants and some neuroleptics. In: Kalow W (ed.). Pharmacogenetics of drug metabolism. Pergamon Press; New York. 1992; 689-700.
16. Küpfer A, Desmond P, Schenker S, Branch RA. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man. Pharmacologist 1979; 21: 173.
17. Goldstein JA, Faletto MB, Romkes-Sparks M et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-52.
18. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-99.
19. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4 megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995; 28: 328-32.
20. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in humans. J. Biol. Chem. 1994; 269: 15419-22.
21. De Morais SMF, Wilkinson GR, Blaisdell J et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 1994; 46: 594-8.